Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

tisagenlecleucel 2fludarabine 2blinatumomab 2Cyclophosphamide 2zanubrutinib 1selinexor 1revumenib 1niraparib 1nilotinib 1ivosidenib 1imetelstat 1ibrutinib 1entrectinib 1dostarlimab 1brexucabtagene autoleucel 1avapritinib 1asciminib 1Standard of Care 1Paclitaxel 1Imatinib Mesylate 1GRN163L peptide 1Drug Therapy 1Dexamethasone 1Dasatinib 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Recurrence × revumenib × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡